The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
Alexis Ioane hesitated before starting tirzepatide, a GLP-1 medication, but two months in, she's shed pounds, gained energy for her kids, and cleared her mind. While GLP-1s like Ozempic and Wegovy promise transformative weight loss, experts caution about mental health effects. Discover the full story on body and mind impacts.
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
New research shows that one night of total sleep deprivation significantly delays the glucagon-like peptide 1 (GLP-1) peak response to breakfast in healthy young men. This finding highlights how sleep loss disrupts key incretin hormones involved in glucose regulation and appetite control. Discover the study's design and what it means for metabolic health.
Grammy-nominated country singer Luke Combs revealed on The New York Times' Popcast why GLP-1 weight loss drugs aren't for him: he wants to 'beat myself' the hard way. Motivated by his wife and kids, Combs embraces the struggle over quick fixes amid lifelong weight battles. His story highlights the personal choice in pursuing metabolic health.
Pfizer is pushing forward on dual fronts: a major $495M deal for Ecnoglutide in China's booming GLP-1 market and full FDA approval for its BRAFTOVI regimen in metastatic colorectal cancer. Clinical data highlights 15.1% placebo-adjusted weight reduction and a 51% drop in mortality risk from the BREAKWATER study. These moves underscore Pfizer's strategy in metabolic and oncology therapeutics.
Health regulators have issued an urgent 'check now' warning to Mounjaro users after counterfeit 15mg KwikPens were dispensed at a Birmingham private clinic. While the fakes contain tirzepatide, unknown manufacturing raises infection risks. Patients are urged to verify their pens immediately.
Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.
Lasso, a food tech innovator, just launched Froobies and CronchClub—two snacks designed for GLP-1 users using proprietary SpinTech that weaves protein and fiber together. With clean ingredients, high macros, and craveable flavors, they address the nutritional demands of the GLP-1 era. Pre-order now and experience real snack innovation.
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
